Business Description
Hybio Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE1000011T7
Share Class Description:
SZSE:300199: Class ACompare
Compare
Traded in other countries / regions
300199.China IPO Date
2011-04-07Description
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 2.61 | |||||
| Debt-to-EBITDA | -7.4 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.2 | |||||
| Beneish M-Score | -3.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -14.6 | |||||
| 3-Year EBITDA Growth Rate | 16.8 | |||||
| 3-Year EPS without NRI Growth Rate | 0.5 | |||||
| 3-Year FCF Growth Rate | 23.2 | |||||
| 3-Year Book Growth Rate | -21.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 75.45 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.68 | |||||
| 9-Day RSI | 46.16 | |||||
| 14-Day RSI | 50.09 | |||||
| 6-1 Month Momentum % | 9.7 | |||||
| 12-1 Month Momentum % | -8.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.43 | |||||
| Quick Ratio | 0.23 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 311.63 | |||||
| Days Sales Outstanding | 147.08 | |||||
| Days Payable | 207.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.2 | |||||
| Shareholder Yield % | -0.44 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.77 | |||||
| Operating Margin % | -36.5 | |||||
| Net Margin % | -90.89 | |||||
| FCF Margin % | 14.79 | |||||
| ROE % | -44.98 | |||||
| ROA % | -11.72 | |||||
| ROIC % | -4.27 | |||||
| ROC (Joel Greenblatt) % | -13.97 | |||||
| ROCE % | -12.92 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 44.33 | |||||
| PS Ratio | 28.74 | |||||
| PB Ratio | 16.63 | |||||
| Price-to-Tangible-Book | 41.56 | |||||
| Price-to-Free-Cash-Flow | 179.7 | |||||
| Price-to-Operating-Cash-Flow | 84.18 | |||||
| EV-to-EBIT | -54.59 | |||||
| EV-to-EBITDA | -54.59 | |||||
| EV-to-Revenue | 33.65 | |||||
| EV-to-FCF | 247.74 | |||||
| Price-to-Median-PS-Value | 1.85 | |||||
| Earnings Yield (Greenblatt) % | -1.83 | |||||
| FCF Yield % | 0.51 | |||||
| Forward Rate of Return (Yacktman) % | 20.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hybio Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 405.055 | ||
| EPS (TTM) (Â¥) | -0.426 | ||
| Beta | 2.57 | ||
| Volatility % | 57.92 | ||
| 14-Day RSI | 50.09 | ||
| 14-Day ATR (Â¥) | 0.802453 | ||
| 20-Day SMA (Â¥) | 13.5115 | ||
| 12-1 Month Momentum % | -8.97 | ||
| 52-Week Range (Â¥) | 8.83 - 15.95 | ||
| Shares Outstanding (Mil) | 883.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hybio Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hybio Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hybio Pharmaceutical Co Ltd Frequently Asked Questions
What is Hybio Pharmaceutical Co Ltd(SZSE:300199)'s stock price today?
The current price of SZSE:300199 is ¥13.30. The 52 week high of SZSE:300199 is ¥15.95 and 52 week low is ¥8.83.
When is next earnings date of Hybio Pharmaceutical Co Ltd(SZSE:300199)?
The next earnings date of Hybio Pharmaceutical Co Ltd(SZSE:300199) is .
Does Hybio Pharmaceutical Co Ltd(SZSE:300199) pay dividends? If so, how much?
Hybio Pharmaceutical Co Ltd(SZSE:300199) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers